2nd Firm Agrees To Temporary Shutdown In Meningitis Outbreak
More: U.S. Meningitis Outbreak
- 10/7/12: Mass. Pharmacy Linked To Meningitis Outbreak Issues Wide Recall
- 10/11: Mass. Pharmacy Industry Resists Call For Stricter Regulation
- 10/15: FDA: Pharmacy’s Other Drugs May Be Causing Illness
- 10/16: Former Regulator Calls For More Oversight Of Pharmacies
- 10/16: Criminal Investigators Visit Framingham Pharmacy
- 10/23: A Trail Of Complaints At Pharmacy Linked To Meningitis Deaths
- 10/24: State Moves To Revoke License Of Firm Tied To Outbreak
- 10/31: Sister Company Of Framingham Pharmacy Recalls Drugs
- 11/7: Mass. Pharmacy Board Director Is Fired
- 11/14: Sec. Bigby: Meningitis Outbreak A ‘Disaster’ That Was ‘Preventable’
- 11/28: In Outbreak Wake, Hospital Pharmacies Step Up Drug Compounding
- 1/4/13: Patrick Proposes New Compounding Pharmacy Rules
Complete Coverage: Meningitis Outbreak
BOSTON — A Massachusetts company run by the same executives who operated a specialty pharmacy linked to a fatal meningitis outbreak has agreed to temporarily shut down for inspection by state and federal regulators.
Ameridose is located in Westborough. The New England Compounding Center, which produced a steroid linked to the outbreak, is in Framingham. Both firms are run by Barry Cadden and Greg Conigliaro.
Ameridose provides sterile medication in prefilled oral syringes to about 3,000 hospitals nationwide. It opened its doors in 2006, eight years after NECC opened.
The Massachusetts Department of Public Health says Ameridose agreed to the shutdown until inspections by state regulators and the U.S. Food and Drug Administration are completed.
There is no recall of Ameridose products.
The outbreak has sickened 137 people in 10 states. Twelve have died.